Randomized, open-label, parallel group, multi-center phase II clinical trial of active cellular immunotherapy with preparation DCVAC/PCa in combination with hormone therapy in patients with metastatic prostate cancer
Phase of Trial: Phase II
Latest Information Update: 29 May 2017
At a glance
- Drugs Stapuldencel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 07 Jun 2017 Biomarkers information updated
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 05 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.